热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 药物靶点和Fc受体 药物靶点

所有图片（1/3）

DcR3 His Tag Protein, Human

Decoy receptor for Fas ligand,TNFRSF6B,TR6,Decoy receptor 3

价格 ￥1,480.00 （ 供应商现货 ： 3-5个工作日）
货号 UA016058
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 物种

    Human

  • 分子别名

    Decoy receptor for Fas ligand, TNFRSF6B, TR6, Decoy receptor 3

  • Accession

    O95407

  • 表达序列

    Val30-His300 with His Tag at the C-Terminus

  • 表达宿主

    HEK293

  • 分子量

    35-40kDa (Reducing)

  • 纯度

    ＞95% by SDS-PAGE

  • 活性

    1.Immobilized DcR3 His Tag Protein, Human (Cat. No. UA016058) at 5.0μg/mL (100μL/well) can bind Human TL1A/TNFSF15 Protein, hFc Tag (Cat. No. S0A4084) with EC50 of 1.13-1.70 ng/ml. 2.Immobilized TL1A/TNFSF15 Protein, hFc Tag (Cat. No. S0A4084) at 5.0μg/mL (100μL/well) can bind Human DcR3 His Tag Protein, Human (Cat. No. UA016058) with EC50 of 16.26-21.17 ng/ml.

  • 标记

    Unconjugated

  • 标签

    His Tag

  • 性状

    Lyophilized Powder

  • 缓冲体系

    PBS, PH7.4, 5% trehalose

  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.

  • 文献引用

    1.Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol. 2011 Apr 1;81(7):838-47.
    2.Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, Nakajima Y. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer. 2002;5(2):61-8.

背景介绍

  • DCR3 (Decoy Receptor 3), also known as TNFRSF6B, is a member of the tumor necrosis factor receptor superfamily. It is a soluble secreted protein lacking both transmembrane and intracellular death domains. DCR3 exerts its "decoy" function by competitively binding to ligands such as FasL, LIGHT, and TL1A, thereby blocking apoptosis signaling induced by these ligands. Beyond its classical anti-apoptotic role, DCR3 can also activate pathways including NF-κB through reverse signaling to regulate dendritic cell differentiation, macrophage polarization, and osteoclast formation, participating in immune modulation and inflammatory responses. Clinical studies have demonstrated that DCR3 is aberrantly elevated in various malignancies (gastric cancer, renal cell carcinoma, pancreatic cancer, etc.) and autoimmune diseases (Crohn's disease, rheumatoid arthritis), serving as a biomarker for disease prognosis assessment. Furthermore, neutralizing antibodies or siRNA-based interventions targeting DCR3 offer potential therapeutic strategies for tumor immunotherapy.

  • 电泳

    • 1μg (R: reducing condition, N:non-reducing condition).

  • ELISA

    • Immobilized DcR3 His Tag Protein, Human (Cat. No. UA016058) at 5.0μg/mL (100μL/well) can bind Human TL1A/TNFSF15 Protein, hFc Tag (Cat. No. S0A4084) with EC50 of 1.13-1.70 ng/ml.

    • Immobilized TL1A/TNFSF15 Protein, hFc Tag (Cat. No. S0A4084) at 5.0μg/mL (100μL/well) can bind Human DcR3 His Tag Protein, Human (Cat. No. UA016058) with EC50 of 16.26-21.17 ng/ml.

评论(0)